These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38978570)
41. Anti-GPC3 single-chain scFv antibody acts as an agent for radio-immunoimaging in diagnosing hepatocellular carcinoma. Guan L; Wu W; Pang H; Duan D; Li S Am J Transl Res; 2019; 11(12):7422-7431. PubMed ID: 31934289 [TBL] [Abstract][Full Text] [Related]
42. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Xu H; Tang Y; Zhao Y; Wang F; Gao X; Deng D; Gu Y Mol Pharm; 2021 May; 18(5):2082-2090. PubMed ID: 33797932 [TBL] [Abstract][Full Text] [Related]
43. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients. Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600 [TBL] [Abstract][Full Text] [Related]
44. Bi-specific T1 positive-contrast-enhanced magnetic resonance imaging molecular probe for hepatocellular carcinoma in an orthotopic mouse model. Ma XH; Chen K; Wang S; Liu SY; Li DF; Mi YT; Wu ZY; Qu CF; Zhao XM World J Gastrointest Oncol; 2022 Apr; 14(4):858-871. PubMed ID: 35582105 [TBL] [Abstract][Full Text] [Related]
45. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)]. Huang W; Liu Y; Hu Y; Gao J Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281 [TBL] [Abstract][Full Text] [Related]
46. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. Zheng X; Liu X; Lei Y; Wang G; Liu M Front Oncol; 2022; 12():824208. PubMed ID: 35251989 [TBL] [Abstract][Full Text] [Related]
48. High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice. Chu Q; Mu W; Lan C; Liu Y; Gao T; Guan L; Fang Y; Zhang Z; Liu Y; Liu Y; Zhang N Int J Nanomedicine; 2021; 16():4161-4173. PubMed ID: 34168446 [TBL] [Abstract][Full Text] [Related]
49. Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications. Lange SE; Zheleznyak A; Studer M; O'Shannessy DJ; Lapi SE; Van Tine BA Oncotarget; 2016 Mar; 7(11):13082-92. PubMed ID: 26909615 [TBL] [Abstract][Full Text] [Related]
50. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185 [TBL] [Abstract][Full Text] [Related]
51. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685 [TBL] [Abstract][Full Text] [Related]
52. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. Haruyama Y; Kataoka H World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876 [TBL] [Abstract][Full Text] [Related]
53. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433 [TBL] [Abstract][Full Text] [Related]
54. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1. Williams SP; Ogasawara A; Tinianow JN; Flores JE; Kan D; Lau J; Go M; Vanderbilt AN; Gill HS; Miao L; Goldsmith J; Rubinfeld B; Mao W; Firestein R; Yu SF; Marik J; Terwisscha van Scheltinga AG Oncotarget; 2016 May; 7(18):25103-12. PubMed ID: 27029064 [TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and Biodistribution of Ghosh S; Fletcher NL; Huda P; Houston ZH; Howard CB; Lund ME; Lu Y; Campbell DH; Walsh BJ; Thurecht KJ Mol Pharm; 2023 Mar; 20(3):1549-1563. PubMed ID: 36602058 [TBL] [Abstract][Full Text] [Related]
56. Zhao M; Dong L; Liu Z; Yang S; Wu W; Lin J Quant Imaging Med Surg; 2018 Mar; 8(2):151-160. PubMed ID: 29675356 [TBL] [Abstract][Full Text] [Related]
57. Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190 [TBL] [Abstract][Full Text] [Related]
58. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083 [TBL] [Abstract][Full Text] [Related]
59. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001 [TBL] [Abstract][Full Text] [Related]
60. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [ Lu Q; Long Y; Fan K; Shen Z; Gai Y; Liu Q; Jiang D; Cai W; Wan C; Lan X Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4000-4013. PubMed ID: 35763056 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]